Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis

Steffen Weikert(St. Hedwig-Krankenhaus), Markus Müller(Charité - Universitätsmedizin Berlin), Hans Krause(Charité - Universitätsmedizin Berlin), Frank Christoph(Charité - Universitätsmedizin Berlin), Kurt Miller(Charité - Universitätsmedizin Berlin), Mark Schrader(Arbeitsgemeinschaft Urologische Onkologie)
International Journal of Cancer
March 10, 2005
10.1002/ijc.21000
Cited by 105

Related Papers

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2015|1.4k
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
|European Urology|2016|414
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial
|The Lancet Oncology|2016|218